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Abstract
Background: Definitive erythropoiesis is a vital process throughout life. Both its basal activity under physiological conditions
and its increased activity under anemia-induced stress conditions are highly stimulated by the hormone erythropoietin. The
transcription factor Sox6 was previously shown to enhance fetal erythropoiesis together and beyond erythropoietin
signaling, but its importance in adulthood and mechanisms of action remain unknown. We used here Sox6 conditional null
mice and molecular assays to address these questions.
Methodology/Principal Findings: Sox6
fl/flErGFPCre adult mice, which lacked Sox6 in erythroid cells, exhibited compensated
anemia, erythroid cell developmental defects, and anisocytotic, short-lived red cells under physiological conditions, proving
that Sox6 promotes basal erythropoiesis. Tamoxifen treatment of Sox6
fl/flCaggCreER mice induced widespread inactivation
of Sox6 in a timely controlled manner and resulted in erythroblast defects before reticulocytosis, demonstrating that
impaired erythropoiesis is a primary cause rather than consequence of anemia in the absence of Sox6. Twenty five percent
of Sox6
fl/flErGFPCre mice died 4 or 5 days after induction of acute anemia with phenylhydrazine. The others recovered slowly.
They promptly increased their erythropoietin level and amplified their erythroid progenitor pool, but then exhibited severe
erythroblast and reticulocyte defects. Sox6 is thus essential in the maturation phase of stress erythropoiesis that follows the
erythropoietin-dependent amplification phase. Sox6 inactivation resulted in upregulation of embryonic globin genes, but
embryonic globin chains remained scarce and apparently inconsequential. Sox6 inactivation also resulted in downregulation
of erythroid terminal markers, including the Bcl2l1 gene for the anti-apoptotic factor Bcl-xL, and in vitro assays indicated that
Sox6 directly upregulates Bcl2l1 downstream of and beyond erythropoietin signaling.
Conclusions/Significance: This study demonstrates that Sox6 is necessary for efficient erythropoiesis in adult mice under
both basal and stress conditions. It is primarily involved in enhancing the survival rate and maturation process of erythroid
cells and acts at least in part by upregulating Bcl2l1.
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Introduction
Erythropoiesis or red blood cell formation is a vital process
throughout life. It first occurs in the yolk sac of the mammalian
embryo. Then referred to as embryonic or primitive erythropoi-
esis, it produces red blood cells (RBCs) that are large, nucleated,
and short-lived, and that contain hemoglobin made with the
products of embryonic globin genes. Embryonic erythropoiesis is
taken over by definitive erythropoiesis when the liver starts
developing around day 10 of mouse gestation. This organ is the
fetus erythropoietic center. It releases RBCs that are small,
enucleated, long-lived, and whose hemoglobin is made with the
products of the alpha and beta adult globin genes. Erythropoiesis
transiently switches to the spleen around birth, before primarily
and definitively homing to the bone marrow. It remains a very
active process throughout postnatal development, constantly
adjusting its RBC output to the growing body size. Under
physiological conditions, a healthy adult mouse or human
maintains a basal level of erythropoietic activity in the bone
marrow, renewing 1–2% of its RBC population on a daily basis. A
number of conditions that result in severe hypoxia force
erythropoiesis to quickly and efficiently increase its output and
eventually renew the entire pool of RBCs in just a few days. This
accelerated process is called stress erythropoiesis and mainly
occurs in the spleen [1]. In the most severe cases, it is triggered by
acute anemia due to hematological disorders, severe blood loss, or
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esis is impaired. It is therefore important to fully understand the
molecular mechanisms that underlie basal and stress erythropoiesis
to be able to propose improved strategies to stimulate stress
erythropoiesis in patients with such conditions.
Basal and stress erythropoiesis occur in several developmental
cell stages and are controlled by complex molecular networks.
Specific transcription factors govern the recruitment of hemato-
poietic stem cells to the erythroid lineage and the sequential
differentiation and maturation of the cells into erythroid
progenitors, proerythroblasts, erythroblasts, reticulocytes, and
erythrocytes [2–4]. Best known are the Gata1 and Fog1 zinc
finger factors, the Eklf erythroid Kru ¨ppel-like factor, and the
Foxo3a forkhead factor [5–10]. Erythroid cell survival and
proliferation are largely controlled by the hormone erythropoietin
(Epo) [11–13], but also by the stem cell factor, glucocorticoids, and
bone morphogenetic protein-4 [14–16]. Epo is produced by the
kidney at a low level under basal conditions, and at a very high
level in response to hypoxia. It binds to a specific receptor, EpoR,
expressed almost exclusively on erythroid cells, and signals
principally through the Jak/Stat and Akt/PI3K pathways. Many
factors necessary for basal erythropoiesis, such as Epo and Gata1,
are also required for stress erythropoiesis [1,17,18]. In contrast,
molecules like the Stat5 transcription factor and Bcl-xL anti-
apoptotic factor are dispensable for basal erythropoiesis, but
essential to ensure the high efficiency of stress erythropoiesis
downstream of Epo [19–22].
Sox6 is a transcription factor with an Sry-related high-mobility-
group DNA-binding (Sox) domain and a highly conserved coiled-
coil homodimerization domain, but with no known transactivation
or transrepression domain [23]. While many Sox proteins are
required for cell fate specification and differentiation in discrete
lineages, Sox6 forms with Sox5 and Sox13 a Sox group (SoxD)
that act as significant modulators rather than obligatory
determinants of cell fate and differentiation. For instance, Sox6
is co-expressed with Sox5 in chondrocytes and the two proteins act
redundantly to potentiate transactivation of cartilage marker genes
by the chondrogenic master Sox9 and thereby to achieve efficient
chondrogenesis [24,25]. Sox5 and Sox6 are also co-expressed and
acting redundantly in oligodendrocytes [26]. Their roles in this
lineage are to delay gliogenesis by blocking the ability of Sox9 and
Sox10 to bind and transactivate oligodendrocyte markers. Sox6
and its relatives thus have the ability to enhance as well as repress
gene transcription. The determinants of their positive and negative
influence on transcription include specific gene sequences and
protein partners [23]. Sox6
2/2 mice die at birth or in the third
week of age with skeletal, glial, and cardiac developmental defects
[24–29]. They also feature a large proportion of nucleated
definitive red blood cells and are anemic, despite an increased
Epo level and liver volume [30]. Sox6, but neither Sox5 nor
Sox13, is expressed in definitive erythroid cells and has cell-
autonomous roles in these cells [30,31]. It potentiates the ability of
Epo to stimulate early erythroid cell survival and proliferation, and
it also facilitates erythroblast and reticulocyte maturation, but the
molecular mechanisms underlying these functions remain un-
known [30]. The embryonic globin genes are currently the only
genes whose expression is known to be altered in Sox6
2/2
erythroid cells. While these genes are silent in normal definitive
erythroid cells, they are highly expressed in Sox6
2/2 cells. Sox6
was shown to bind to the proximal promoter of the embryonic
epsilon-globin gene and to interact with Bcl11a to repress epsilon-
globin gene expression [31,32]. It is unknown, however, whether
ectopic expression of embryonic globins is responsible for the
survival, proliferation or maturation defects of Sox6
2/2 erythroid
cells or whether Sox6 also modulates the expression of other genes
in erythroid cells. Sox6
2/2/wild-type hematopoietic chimeras
were shown to maintain expression of the embryonic epsilon-
globin gene in adulthood and to have misshapen RBCs [33], but
these mice did not address the question of the need for Sox6 in
basal or stress erythropoiesis in adulthood.
In light of the importance of basal and stress erythropoiesis in
adulthood, we undertook the present study to further uncover the
importance and molecular roles of Sox6 in this process. We show
that Sox6 continues to enhance erythroid cell development
throughout adulthood in the mouse. Its contribution is significant
in basal erythropoiesis and critical to ensure mouse survival and
prompt recovery in stress erythropoiesis. Embryonic globins are
scarce in the developing erythroid cells and RBCs of Sox6 mutants
and their presence appears inconsequential. Sox6 effectively
upregulates the expression of multiple late erythroid cell markers,
and one of its direct targets is Bcl2l1, which encodes Bcl-xL, an
important survival factor acting downstream and beyond Epo
signaling in erythroid cells.
Materials and Methods
Mouse generation and analysis
Mice were used according to federal guidelines and as approved
by the Cleveland Clinic Institutional Animal Care and Use
Committee (protocol ARC 8511, originally approved on
11.29.2007 - latest annual renewal approved 11.24.2009). They
were carrying Sox6 null alleles [25], Sox6 conditional null alleles
[34], an ErGFPCre transgene [35], or a CaggCreER transgene [36],
as described. Tamoxifen (Sigma-Aldrich, St Louis, MO) was
dissolved at 20 mg/ml in corn oil and injected intraperitoneally at
9 mg per 40 g mouse 3 times at 2-day intervals [36]. Phenylhy-
drazine (Sigma) was dissolved at 6 mg/ml in PBS and injected
intraperitoneally at 60 mg/kg on two consecutive days [37]. All
mice were on a mixed 1296 C57BL/6J genetic background.
Complete blood cell tests, serum Epo level assays, fluorescence-
activated cell sorting (FACS) analyses, and globin chain and ghost
analyses were performed as described [30]. CD44 antibody was
purchased from BD Biosciences (San Jose, CA). The life span of
RBCs was measured by injecting 3 mg EZ-Link-sulfo-NHS-Biotin
(Pierce, Rockford, IL) in adult mice and measuring the decay of
labeled RBCs by fluorescence-activated cell sorting (FACS) using
streptavidin-phycoerythrin [38]. FACS was carried out using an
LSRII instrument (BD Biosciences) and data were analyzed using
FlowJo software (Tree Star, Ashland, OR). For the assay of
reactive oxygen species (ROS), blood cells were suspended in PBS
supplemented with 2% FCS and loaded with 5 mM 5-(and 6-)-
chloromethyl-29,79-dichlorodihydrofluorescein diacetate (CM-
H2DCFDA; Invitrogen, Carlsbad, CA) in the dark for 20 minutes
at 37uC, 5% CO2. The oxidative conversion of CM-H2DCFDA
to its fluorescent product was measured immediately by flow
cytometry. A positive control was created by incubating cells with
3 mM tert-butylhydroperoxide (Invitrogen). Western blot with a
hemoglobin beta/gamma/delta/epsilon antibody (SC-22718,
Santa-Cruz Biotechnology, Santa Cruz, CA) was performed using
a standard protocol.
RNA assays
Northern blot was performed with total RNA as described [30].
Probes were generated by RT-PCR and cloned in pCR4-TOPO
(Invitrogen). Globin probes were generated using primers as
described [31]. A 559-bp Bcl2l1 probe was made using the forward
primer (FP) TGGTCGACTTTCTCTCCTAC and reverse prim-
er (RP) AGAGATCCACAAAAGTGTCC. A 592-bp Rnf11 probe
Sox6 in Erythropoiesis
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and TGGCTGCAGATGTTGAGGGAAGTA (RP); a 620-bp
Tmcc2 probe was made using TGCTGAGCCTAGAGAGTGCA-
GAAA (FP) and ATCGAACACAACACTCCAGAGCCT (RP);
and a 678-bp Xpo7 probe was made using ATGCTGAGAGGGC-
CAAGTTTCTCT (FP) and GCTCACCATCCATTGCATC-
TTGCT (RP). Gene expression microarray screening and real-
time RT-PCR were performed essentially as described [39].
Briefly, complementary RNA was hybridized to Illumina Mou-
seRef-8 v2 expression bead chips (Illumina, San Diego, CA).
Genes differentially expressed by at least 1.5 fold in 3 independent
experiments were identified and analyzed in volcano plots using
GeneSpeed Beta Cell software [40]. Venn diagrams were
generated using BioVenn software [41]. For real-time RT-PCR,
cDNA was amplified with gene-specific primers using SYBR green
PCR master mix on an ABI PRISM 7900HT qPCR instrument
(Applied Biosystems, Foster City, CA). Relative mRNA levels were
calculated using the 2
2DDCT method. FP and RP primers were,
respectively, as follows: Bcl2l1 GCTGCATTGTTCCCGTAGAG
and GTTGGATGGCCACCTATCTG; Cd59a GCCTCA-
CATGCTACCACTG and CCAACACCTTTGATACACT-
TGC; Cd59b FPTTCTGGCTGTCTTCTGTTCC and TTGA-
TACACTTGCCTTCCGG; Eif5 CGTGTCGACCAGTTCTATCG
and CTTGATTCCATTTCCTTTGCCC; Lmo2 CATCGAAAGGAA-
GAGCCTGG and GTACTGGTCGATGGCTTTCAG; Rnf11 GGAG-
TTTATGACCCTGGAAGAG and CAGTCCAGGTGATAGATGTGC;
St5 CCAGGGAAAACCATCAAAGTG and AGATTCGGATAAGCT-
GACGC; Tmcc2 GAACTGCGGGAGATAAAGGAG and TGTT-
CCTCCAGCCTCTCATA; and Xpo7 CCTATATCACATC-
CCGCTTGG and TTCTCATACTCACAACGCCC.
In vitro cultures and assays
Erythroid colony formation assays and primary erythroid cell
cultures were performed as described using the whole cell
populations of adult erythropoietic tissues and TER119
2 fetal
liver cells, respectively [30,42]. Reporter assays performed as
described [39]. Briefly, Cos-1 cells were transfected with
FuGENE6 (Roche, Madison, WI), a mouse Bcl2l1 reporter, a
Sox6 [24], constitutively active Stat5 [21] or empty expression
plasmid, and a pSV2betaGal plasmid as control for transfection
efficiency. The Bcl2l1 reporter was made by cloning a 2.8-kb
Bcl2l1 gene fragment containing the upstream enhancer [43],
promoter, first exon and intron, and second exon up to the first
codon into the pGL3 basic reporter plasmid (Promega, Madison,
WI). This fragment was amplified from mouse genomic DNA
using AAGATCAAGGGCAGCCCAC (FP) and CCATGGTC-
CAAAACACCTGCTCACTTACTG (RP). Chromatin immuno-
precipitation was performed as described [39]. Briefly, 3610
6 cells
were crosslinked with 0.5% formaldehyde for 10 min followed by
addition of glycine at 125 mM. Chromatin was sheared by
sonication to fragments averaging 400 bp in buffer containing 1%
SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1 and protease
inhibitor cocktail (Sigma-Aldrich). Chromatin was pre-cleared on
protein G-coupled Dynal magnetic beads (Invitrogen) followed by
immunoprecipitation with antibodies against Sox6 [24] or Stat5
(sc-836X, Santa-Cruz Biotechnology) coupled to protein G-
coupled Dynal magnetic beads. No antibody and non-immune
IgG were used as controls. TGGAAGTCCCTTTAG-
GGTTTCGGA (FP) and TGGTTCCTCCATCGACCAGAT-
CAA (RP) amplified a 236-bp Bcl2l1 promoter region; TGT-
TGGACACCGACATCGAAAGGA (FP) and AGAAAGG-
GACTGGCATCGAGACAT (RP) amplified a 177-bp Bcl2l1
first-intron region; and TGAGTCCTATCCTGGGAACCATCA
(FP) and ATTTATAGGAACCCGGATGGTGGG (RP) ampli-
fied a 284-bp Gapdh promoter region. PCR was done with 1 cycle
at 94uC for 3 min; 40 cycles at 94uC for 20 sec, 59uC for 30 sec,
and 72uC for 30 sec; and 1 cycle at 72uC for 10 min.
Statistical analysis
Numerical values were expressed as means 6 SD. The
significance of differences between control and mutant mice was
determined using the statistical Student’s t-test. A p value less than
0.05 was considered significant.
Results
Sox6 is needed to facilitate erythroid development and
RBC survival in basal erythropoiesis
Sox6 was previously shown to be expressed in definitive
erythroid cells in mouse fetuses and one-week-old pups, but was
not tested in adult mice [30]. Using total RNA from bone marrow
and spleen of 6-, 10-, and 20-week-old mice, we found that Sox6
remained highly expressed in bone marrow throughout adulthood
(Fig. 1A). It was also highly expressed in the spleen of young adults,
but became downregulated as mice aged. Expression of the adult
beta-globin gene similarly decreased with age, reflecting fading of
erythropoietic activity in this organ under steady-state conditions
for erythropoiesis.
To test whether Sox6 controls erythropoiesis in adulthood, we
generated mice harboring Sox6 conditional null alleles (Sox6
fl/fl)
[34] and the ErGFPCre allele [35]. ErGFPCre is an EpoR knock-in of
a gene encoding GFP fused to Cre recombinase. It is highly and
specifically expressed in erythroid cells. Sox6 RNA was undetect-
able in the bone marrow and spleen of 10-week-old Sox6
fl/flErGFPCre
mice, proving efficient inactivation of Sox6 in erythroid cells
(Fig. 1B). These mice looked externally normal at all ages and
complete blood cell counts (CBC) revealed that most of their
blood parameters were normal (Fig. 1C; BD and VL, unpub-
lished data). Noticeably, however, their hemoglobin level,
hematocrit, and RBC mean cell volume were 5 to 13% lower
than normal; they had a 16% increase in red cell distribution
width, reflecting RBC anisocytosis, and a 47% increase in
reticulocyte count, revealing reticulocytosis; moreover, their
serum Epo level (sEpo) was 183% as high as normal, and their
spleen was 152% as large as normal. In standard colony-forming
assays in vitro, mutant spleen cells generated 32% more erythroid
colony-forming units (CFU-Es) than wild-type cells and, although
they were slower than controls, they eventually generated 50%
more erythroid burst-forming units (BFU-Es) than controls
(Fig. 1D). These data thus indicated that Sox6 ablation in
erythroid cells results in compensated anemia in adult mice.
To uncover the cause of this phenotype, we analyzed
erythropoietic tissues by FACS. We first used antibodies against
CD71 (transferrin receptor) to label late proerythroblasts and
erythroblasts, and antibodies against TER119 (glycophorin A-
associated protein) to label erythroblasts (Fig. 1E). Mutant bone
marrow and spleen tissues showed identical phenotypes, with 25–
28% fewer non-/early erythroid cells (CD71
2/TER119
2) than
control tissues, and a 35–38% increase in the ratio of erythroblasts
(CD71
+/TER119
+) to late proerythroblasts (CD71
+/TER119
2).
Using an antibody against the CD44 cell adhesion glycoprotein
[44], we found that the size of two populations of developing
erythroid cells was significantly altered in mutant tissues: the
proerythroblast population (CD44
high/TER119
2) and the eryth-
roblast population (CD44
med/TER119
+) (Fig. 1F). The population
of non-erythroid and erythroid precursor cells (CD44
2/med/
TER119
2) appeared unchanged, and we therefore used it to
calculate that the population of proerythroblasts was depleted by
Sox6 in Erythropoiesis
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with an enlargement of 60%. We further analyzed the erythroblast
population using the thiazole orange (TO) nucleic acid dye to
measure chromatin condensation and enucleation, and using the
cell forward scatter to measure cell condensation. We thereby
found that the increased proportion of erythroblasts in mutant
tissues was due to a 3-fold increase in the ratio of uncondensed
(FSC
high/TO
high) versus condensed erythroblasts (FSC
low/
TO
med), i.e., early versus late erythroblasts (Fig. 1G). We reached
the same conclusion when we analyzed the cells using their FSC
and CD44 antibodies instead of TO (data not shown). These data
thus demonstrated that Sox6 is needed in adult mice to facilitate
the development of erythroid cells. It is importantly needed at the
proerythroblast stage and critically needed at the erythroblast
stage.
We then analyzed circulating RBCs. We observed that mature
RBCs (TO
2/CD71
2) accounted for more than 95% blood cells in
control mice, as expected, but for only 70% blood cells in mutant
mice (Fig. 1H). In addition, while 67% control reticulocytes
(CD71
+ and/or TO
+) were retaining RNA longer than CD71
(TO
+/CD71
low/2), 81% mutant reticulocytes were maintaining
CD71 longer than RNA (TO
2/CD71
+). Reticulocytes were thus
maturing slowly and abnormally in mutant mice.
Finally, decay profiling of biotin-labeled cells revealed that
RBCs had a half-life reduced to 19 days in mutant mice compared
to 25 days in control mice (Fig. 1I). We concluded that adult mice
Figure 1. Sox6 is expressed and needed in erythropoietic tissues of adult mice under physiological conditions. (A) Northern blot of
RNA from liver at embryonic day 14.5 (E14.5), and marrow and spleen at 6, 10, and 20 weeks. RNA was detected with Sox6 coding-exon-2 and beta-
globin (Hbb-b1) probes. 18S rRNA stained with ethidium bromide is shown as loading control. The decrease in Sox6 and Hbb-b1 RNA level in 10-week
marrow probably reflects sample variation. (B) Northern blot of RNA from marrow and spleen of 10-week-old Sox6
fl/fl (C) and Sox6
fl/flErGFPCre (M)
mice. The Sox6 probe was the coding exon 2, which is deleted in mutants. (C) Blood parameters and spleen index (percentage of spleen/body
weight) in similar mice as in B. Averages with standard deviation are shown for 6 mice. Red, abnormal parameters. WBC, white blood cells; MCHC,
mean cell hemoglobin concentration; RDW, red cell distribution width. (D) Erythroid colony formation assay using Sox6
fl/fl (C) and Sox6
fl/flErGFPCre (M)
adult spleen. CFU-Es were counted after 3 days and mature BFU-Es after 3, 4, and 7 days. Columns, average with standard deviation obtained for 3
mice. **p,0.01.( E) FACS using CD71 and TER119. Left, representative profiles. CD71
2/TER119
2, non- and early erythroid cells; CD71
+/TER119
2, late
proerythroblasts; CD71
+/TER119
+, erythroblasts; CD71
2/TER119
+, RBCs. The percentage of cells in each population is indicated. Right, ratios of
erythroblasts (EB)/late proerythroblasts. The data in panels (E–H) are averages with standard deviation for 3 mice. **p,0.01.( F) FACS using CD44 and
TER119. Left, representative profiles. Right, ratios of proerythroblasts (CD44
high/TER119
2)/non-erythroid (NE) and erythroid precursors (EP; CD44
2/
med/TER119
2); and erythroblasts (CD44
high/TER119
2)/non-erythroid and erythroid precursors. *p,0.05, **p,0.01.( G) FACS of erythroblasts (TER119
+/
CD71
+). Left, representative TO/FSC profiles. Right, ratios of FSC
high/TO
high uncondensed versus FSC
low/TO
low condensed erythroblasts. **p,0.01.( H)
FACS of blood. Left, representative TO/CD71 profiles. Right, percentages of atypical reticulocytes (CD71
+/TO
2). **p,0.01.( I) Decay profiles of biotin-
labeled RBCs. Each value is average with standard deviation for 6 mice. Arrows, RBC half-lives.
doi:10.1371/journal.pone.0012088.g001
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erythroid cells exhibited compensated anemia, with underdevel-
opment of proerythroblasts, impaired maturation of erythroblasts
and reticulocytes, and decreased survival of RBCs.
Impaired erythroid development is a primary cause of
anemia upon Sox6 inactivation
We next tested whether the abnormal development of erythroid
cells in Sox6
fl/flErGFPCre mice was a direct consequence of Sox6
inactivation or was due to anemia-induced stress erythropoiesis as
a result of reduced survival or malfunction of RBCs. We generated
Sox6
fl/fl adult mice harboring a widely expressed CaggCreER
transgene [36]. This transgene encodes a fusion of Cre
recombinase with a mutant estrogen ligand-binding domain,
which exclusively binds tamoxifen (TM). The CreER protein is
thus able to recombine genes only when mice are treated with
TM. Sox6
fl/flCaggCreER mice showed no visual sign of disease
before and for at least one month after TM injection (BD and VL,
unpublished data). The Sox6 RNA level was normal in bone
marrow and spleen before treatment, and became undetectable 7
and 14 days after treatment (Fig. 2A). CBC parameters remained
normal for at least 2 weeks (Fig. 2B; and, BD and VL, unpublished
data). The ratio of uncondensed versus condensed erythroblasts
doubled within the first week (Fig. 2C), but abnormal reticulocytes
appeared in the circulation only in the second week (Fig. 2D).
Developing erythroid cells thus became abnormal before the
reduced lifespan or other defects of mutant RBCs became
consequential, indicating that impaired erythroid cell maturation
is a primary cause of anemia upon Sox6 inactivation.
Sox6 is critically needed for efficient stress erythropoiesis
The relatively mild erythroid defects of Sox6
fl/flErGFPCre adult
mice in basal conditions prompted us to determine whether this
phenotype would be exacerbated in stress erythropoiesis. We
induced acute anemia by injecting Sox6
fl/fl and Sox6
fl/+ErGFPCre
control mice and Sox6
fl/flErGFPCre mutant mice with phenylhy-
Figure 2. Sox6 is primarily needed for erythroid cell maturation under adult physiological conditions. (A) Northern blot of bone marrow
RNA collected 0, 7 and 14 days after initiation of TM treatment of 10-week-old Sox6
fl/fl control (C) and Sox6
fl/flCaggCreER mutant (M) mice. Sox6 RNA
was detected using a coding-exon-2 probe. Hybridization with an Hbb-b1 probe and staining with ethidium bromide of 18S rRNA are shown as
controls for RNA loading. (B) Blood parameters in similar mice as in panel (A). Data are reported as average values with standard deviation obtained
for 3 mice per genotype. Other blood parameters measured by the ADVIA instrument and not shown in this table were normal in mutant mice. (C)
FACS analysis of erythroblasts in the bone marrow of mice treated as in panel (A). Left, representative FSC/TO FACS profiles of TER119
+/CD71
+ cells.
Right, ratios of uncondensed/condensed erythroblasts. The data are presented as the average with standard deviation of values obtained for 3 mice
per genotype. (D) FACS analysis of blood from the same mice as in panel (C). Left, representative TO/CD71 FACS profiles. Right, ratios of atypical
reticulocytes (TO
2/CD71
+). *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0012088.g002
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pre-existing RBCs decayed in control mice within a week (Fig. 3A).
A similar decay was observed in mutant mice, demonstrating
similar sensitivity of mutant and control RBCs to PHZ. The
hematocrit of all mice decreased by half within 2 days (Fig. 3B).
Control mice started to recover by day 4 and all survived and
regained a normal hematocrit by day 10 (Fig. 3B and C). In
contrast, mutant mice maintained a low hematocrit for at least two
more days and 25% of them died at day 4 or 5. The survivors
started to recover by day 7, but their hematocrit was still 10–15%
lower than normal at day 10.
A quick, massive surge in sEpo level is a critical, early response
to acute anemia. This surge occurred similarly in control and
mutant mice and led to a maximal sEpo level from day 2 to day 4
(Fig. 3D). The sEpo level returned to its basal value by day 7 in
control mice, but only by day 10 in mutants (Fig. 3D). Hence, the
sEpo level was not responsible for the impaired recovery of
mutants. Stress erythropoiesis also involves hyperplasia of the
spleen, due to erythropoietic burst. Control spleens enlarged about
8 times by day 4 and returned to their original size after day 10
(Fig. 3E). Mutant spleens reached the same final size several days
later despite a larger original size and normal surge in sEpo level,
and returned to their original size by day 14 only. Sox6 thus
critically participates in the erythropoietic burst generated in
response to acute anemia. Supporting this conclusion, the Sox6
RNA level strongly increased in control bone marrow and spleen
by day 4 and through day 7, and remained undetectable in mutant
tissues (Fig. 3F). Interestingly, the Sox6 RNA level increased as the
sEpo level surge was fading, but it coincided with the time of death
of mutant mice and with the delay in enlarging the spleen and
regaining a normal hematocrit. Sox6 thus participates in stress
erythropoiesis mostly beyond the Epo-dominated early phase.
Sox6 ensures timely maturation of erythroid cells in stress
erythropoiesis
To identify the contribution of Sox6 in stress erythropoiesis, we
analyzed erythropoietic tissues and blood samples of PHZ-treated
Sox6
fl/fl and Sox6
fl/flErGFPCre mice. From day 2 to day 7 post
treatment, control and mutant mice increased the proportion of
erythroblasts (CD71
+/TER119
+) versus late proerythroblasts
(CD71
+/TER119
2) 10–20 fold in bone marrow and spleen
(Fig. 4A and B). Interestingly, the proportion of uncondensed to
condensed erythroblasts increased up to 2 fold in control mice and
up to 5 fold in mutant mice under stress erythropoiesis (Fig. 4C).
Sox6 thus ensures speedy maturation of erythroblasts in both basal
and stress erythropoiesis.
Reticulocytes could not be detected in the week that followed
PHZ injection, likely due to interference of PHZ with RNA dyes
(BD and VL, unpublished data). We therefore assayed reticulo-
cytes using CD71 antibody only. The quick recovery of control
mice from acute anemia could be explained by an increase in
reticulocyte percentage that became significant by as early as day
3 and that remained at 20–30% between day 5 and day 8 before
returning to normal by day 10 (Fig. 4D). In contrast, the inability
of mutant mice to quickly recover could be explained by failure to
increase the reticulocyte percentage before day 5. Surprisingly,
this parameter became almost twice as high as in control mice
from day 5 and remained elevated until mice fully recovered. By
day 7, when all RBCs were less than 1-week old (Fig. 3A), almost
50% of them were already mature in control mice, but less than
20% were mature in mutants (Fig. 4E). By day 10, about 90%
RBCs were mature in control mice, but only about 50% were
mature in mutants. Sox6 thus critically intervenes in stress
erythropoiesis to ensure prompt maturation of erythroblasts and
reticulocytes.
Figure 3. Sox6 is needed in the stress erythropoietic response to acute anemia. (A) Kinetics of RBC decay in Sox6
fl/fl and Sox6
fl/+ErGFPCre
control and Sox6
fl/flErGFPCre mutant mice over a period of 2 weeks following PHZ treatment. RBCs were labeled with biotin at day –1 and PHZ was
injected at the days 0 and 1. The data are presented as the average with standard deviation of values obtained for 3 mice per genotype. (B) Kinetics
of hematocrit changes in control and mutant mice following PHZ treatment. Each data is the average with standard deviation of values obtained for 3
mice. Different mice were used at each time point. (C) Mouse survival curves following PHZ treatment. At day 3, each experimental group contained
24 mice. All mice survived in the control groups, whereas 3 mice died at day 4, and 3 at day 5 in the mutant group. (D) Kinetics of sEpo level in the
same mice as in panel (B). (E) Kinetics of spleen index in the same mice as in panel (B). (F) Northern blot analysis of Sox6 RNA level in the bone
marrow and spleen of Sox6
fl/fl control and Sox6
fl/flErGFPCre mutant mice at various time points following PHZ treatment. Sox6 RNA was detected using
a coding-exon-2 probe. Hybridization with an Hbb-b1 probe and staining with ethidium bromide of 18S rRNA are shown as controls for RNA loading.
*p,0.05, **p,0.01.
doi:10.1371/journal.pone.0012088.g003
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erythroid terminal markers
To better understand how Sox6 controls erythroid cell
development, we screened gene expression microarrays with bone
marrow and spleen RNA from Sox6
fl/fl and Sox6
fl/flErGFPCre
littermates at 3 months of age under physiological conditions and 4
days after induction of acute anemia by PHZ. Volcano plots of p
values against gene expression fold changes revealed that the
embryonic epsilon globin gene (Hbb-y) was by far the most affected
gene, with an upregulation fold of more than 200 in all mutant
samples (Fig. 5A).
Hbb-y was previously shown to be a direct target of Sox6 in
erythroid cells [31,32], but it was not shown whether its ectopic
expression impaired the development of erythroid cells. We tested
this possibility because imbalanced production of globin chains in
thalassemia results in impaired maturation and survival of
erythroid cells in a manner resembling the Sox6-null phenotype
[45,46]. Northern blot analysis revealed that the embryonic globin
genes were expressed at a much lower level than adult globin
genes in Sox6-null erythroid cells (Fig. 5B). Accordingly, embryonic
globin chains were hardly if at all detected in RBC lysates (Fig. 5C).
A detrimental consequence of the imbalanced production of
globin chains in thalassemia is precipitation of globin chains in
erythroid membranes. Precipitated chains can be detected in
ghosts, i.e., red blood cell membrane extracts. Sox6-null ghosts
contained ectopic proteins with an Mr close to 15 and 30k
(Fig. 5D). These proteins, however, did not react with an antibody
against beta, gamma, delta and epsilon globins (Fig. 5E and F),
and mass spectrometry analysis revealed that the 15k and 30k
species largely corresponded to H2a/2b and H1 histones,
respectively, and did not contain any globin chain (PD and VL,
unpublished data). These histones thus reflected the fact that Sox6
mutant mice release a significant proportion of nucleated erythroid
cells in the circulation [30]. Another consequence of the abnormal
production of globin chains in thalassemia is the generation of
reactive oxygen species (ROS) [47]. ROS are very detrimental to
Figure 4. Sox6 ensures quick maturation of erythroblasts and reticulocytes during stress erythropoiesis. (A) Representative CD71/
TER119 FACS profiles of bone marrow and spleen from Sox6
fl/fl control (C) and Sox6
fl/flErGFPCre mutant (M) mice 0, 2, and 4 days after PHZ treatment.
Note that a massive increase in CD71
2/TER119
+ cells occurred in control and mutant spleens at day 2, reflecting clearance of damaged RBCs. (B)
Kinetics of the proportions of erythroblasts versus proerythroblasts in bone marrow and spleen of control and mutant mice from day 0 to day 10
following PHZ treatment. Values were derived from CD71/TER119 FACS profiles and are presented as the average with standard deviation for 3 mice
per genotype at each time point. (C) Kinetics of the proportions of uncondensed versus condensed erythroblasts. Values were derived from FSC/TO
FACS profiles performed with the same cell populations as in panel (B). (D) Kinetics of the percentage of reticulocytes (CD71
high) present in the blood
of control and mutant mice following PHZ treatment. Values are presented as the average with standard deviation for at least 3 mice per genotype at
each time point. (E) Representative TO/CD71 FACS profiles of blood cells from control and mutant mice 7 and 10 days after PHZ treatment. *p,0.05,
**p,0.01.
doi:10.1371/journal.pone.0012088.g004
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production was not increased in the blood of Sox6-null mice
(Fig. 5G). Together, these data thus indicated that the abnormal
erythroid phenotype of Sox6 mutant mice is unlikely due to ectopic
expression of embryonic globin genes.
Besides Hbb-y upregulation, most other gene expression changes
were less than 4-foldinSox6 mutant samples (Fig. 5A). Few genes had
their expression changed under both steady-state and erythropoietic
stress conditions, but many genes had their expression affected
in both bone marrow and spleen under stress erythropoiesis
(Fig. 6A and Table S1). We selected a subset of upregulated and
downregulated genes according to their known or predicted functions
and fold expression change, and validated their expression changes
by quantitative RT-PCR using RNA from fetal liver and from
samples similar to those used for the microarrays. We confirmed that
the genes for CD59a and CD59b, which restrict the lysis of human
erythrocytes and leukocytes by the homologous complement, tended
to be upregulated in the bone marrow and spleen of Sox6 mutant
mice (Fig. 6B). All selected downregulated genes were confirmed in
this assay and in northern blot (Fig. 6B and C). They included Bcl2l1,
which encodes the anti-apoptotic factor Bcl-xL; Eif5, which encodes
the eukaryotic translation initiation factor 5; Lmo2, which codes for
the LIM-domain only factor 2 and is critically needed for
hematopoietic development; Rnf11, which codes for the E3 ubiquitin
ligase ring finger factor 11; St5, which codes for the suppressor of
tumorigenicity 5 factor; Tmcc2, t h eg e n ef o rt h et r a n s m e m b r a n ea n d
coiled-coil domain family 2; and Xpo7, the gene for exportin 7. Most
of these genes were upregulated at day 4 and 7 during stress
erythropoiesis in wild-type mice, coincidentally with erythroid
terminal maturation and Sox6 expression (Fig. 3F and 6D). They
were also upregulated when wild-type erythroid cells were reaching
the early and late erythroblast stages at 24 and 48 h in primary
cultures, respectively (Fig. 6E). These data thus indicated that Sox6 is
needed to upregulate expression of late erythroid markers.
Bcl2l1 was previously shown to mediate erythroid cell survival
and to be a direct target of the transcription factor Stat5
downstream of Epo signaling [19–21]. Interestingly, we found
that upregulation of Bcl2l1 expression in response to Epo signaling
required Sox6 (Fig. 6F). Furthermore, Sox6 was able to upregulate
a Bcl2l1 reporter containing the most highly conserved non-coding
Figure 5. Embryonic globin and other gene expression changes in Sox6-deficient erythropoietic tissues and primary erythroid cells.
(A) Volcano plots showing gene expression changes in mutant tissues. RNA was from bone marrow of Sox6
fl/fl and Sox6
fl/flErGFPCre mice before PHZ
treatment (day 0) [left]; bone marrow [middle] and spleen [right] of similar mice 4 days after treatment. Each dot represents a gene probe. Green
circles highlight Hbb-y identified by two probes. (B) Northern blot of globin RNA levels in spleen of Sox6
fl/fl (C) and Sox6
fl/flErGFPCre (M) mice 0 to 7
days after PHZ treatment. Probes were for adult alpha-globin (Hba-a1) and beta-globin (Hbb-b1), and embryonic X-globin (Hba-x), Y-globin (Hbb-y),
and Z-globin (Hbb-z). All had similar specific activity and length. X-ray films were exposed for 30 min for adult globin RNAs, and 4 days for embryonic
globin RNAs. The latter were thus weakly expressed compared to the former. (C) Electrophoretic analysis of globins in RBCs from E12.5 wild-type
embryo and control and mutant adult mice 0 and 4 days after PHZ treatment. Globin chains are indicated. Several beta-globin isoforms are seen due
to mixed genetic background. (D) RBC ghosts from 3-day-old (P3) Sox6
+/+, Sox6
+/2, and Sox6
2/2 littermates, and 4-month-old Sox6
fl/fl (C) and Sox6
fl/
flErGFPCre (M) mice 0 day (steady-state) and 4 days (stress erythropoiesis) after PHZ treatment. Protein marker molecular weights and typical RBC
proteins are indicated. Blue arrows, ectopic histones in mutants. Red arrows, proteins reacting with hemoglobin antibody against beta-, gamma-,
delta-, and epsilon-globins. (E) Coomassie blue staining of globins in RBC lysates from control mice at E13.0, E15.5, and postnatal day 7 (P7) and
western blot with hemoglobin antibody. (F) Western blot of ghosts from P3 mice with hemoglobin antibody. Red arrows, all samples have similar
residual globin chains. (G) Flow cytometry shows that minimal ROS production in blood of control and mutant adult mice, except in control blood
treated with tert-butyl hydroperoxide (TBHP).
doi:10.1371/journal.pone.0012088.g005
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promoter and first intron (Fig. 6G). These regions were previously
shown to control Bcl2l1 expression in erythroid cells in response to
Epo signaling [21,43]. Sox6 was as potent as constitutively active
Stat5 in upregulating the activity of the Bcl2l1 reporter, and
the two factors had additive effects. Additionally, a chromatin
immunoprecipitation assay in wild-type fetal liver cells provided
evidence that Sox6, like Stat5, directly binds to the promoter and
first intron of the endogenous Bcl2l1 gene in erythroid cells in vivo
(Fig. 6H). These data thus strongly suggest that Bcl2l1 is a direct
target of Sox6 downstream of Epo signaling and during erythroid
terminal maturation.
Discussion
This study has uncovered that Sox6 is expressed in erythroid
cells throughout life and acts as a significant enhancer of both
basal and stress erythropoiesis in the adult mouse. Sox6 has
important roles in the development of proerythroblasts and also
has critical roles in promoting maturation of erythroblasts and
reticulocytes and in extending the life span of RBCs. Its ability to
repress the embryonic globin genes appears inconsequential. In
contrast, its ability to directly enhance Bcl2l1 expression likely
contributes to its ability to work with and beyond Epo signaling in
promoting erythroid cell survival.
We demonstrated that Sox6 significantly contributes to ensuring
efficient basal erythropoiesis by showing that Sox6
fl/flErGFPCre
adult mice had compensated anemia. Clear signs of compensation
included an increase of up to 2 fold of the reticulocyte count, sEpo
level, spleen size, and a 32–50% increase in the number of
erythroid colonies developing in vitro from spleen cells. It is very
likely that erythroid defects are the cause of this anemia since wild-
type adult mice strongly express Sox6 in erythropoietic tissues and
since Sox6
fl/flErGFPCre mice inactivate Sox6 only in erythroid
Figure 6. Characterization of Bcl2l1 and other gene expression changes in Sox6-deficient tissues and cells. (A) Venn diagram showing
the number of genes upregulated or downregulated at least 1.5 fold (p#0.1)i nSox6 mutant samples. BM0, bone marrow before PHZ treatment; BM4,
bone marrow 4 days after PHZ treatment; Sp4, spleen 4 days after PHZ treatment. (B) Real-time RT-PCR validation of a subset of genes significantly
upregulated or downregulated in Sox6 mutant samples in microarrays. At least three mice were used for each type of samples. FC, fold change. (C)
Northern blot of total RNA from the liver of Sox6
+/+ (C) and Sox6
2/2 (N) littermates at E14.5, and from the bone marrow of Sox6
fl/fl (C) and Sox6
fl/
flErGFPCre (M) adult mice under physiological conditions. Hybridization was with the indicated probes. (D) Northern blot of total RNA from the spleen
of Sox6
fl/fl (C) and Sox6
fl/flErGFPCre (M) mice 0 to 10 days after PHZ treatment. (E) Northern blot of total RNA from TER119
2 liver cells isolated from
E14.5 control (C) and Sox6
2/2 (N) fetuses and cultured in erythroid differentiation medium for 0, 24, and 48 h. Most cells are at the early or late
erythroblast stage by 24 and 48 h, respectively [30]. (F) Northern blot of total RNA from TER119
2 liver cells isolated from E14.5 control (C) and Sox6
2/
2 (N) fetuses and cultured in erythroid differentiation medium for 24 h with the indicated Epo concentrations. (G) Transient transfection of Cos-1
mesenchymal cells with a Bcl2l1 construct and expression plasmids for Sox6 and constitutively active Stat5. Assays were performed in triplicates and
are presented as the average with standard deviation for one representative experiment. **p,0.01. (H) Chromatin immunoprecipitation assay in
mouse fetal liver. Chromatin was precipitated with the indicated antibodies. PCR was performed with immunoprecipitated and input chromatin
fragments using primers to amplify the Gapdh promoter (negative control), and the Bcl2l1 promoter and intron 1.
doi:10.1371/journal.pone.0012088.g006
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Sox6
fl/flErGFPCre mice had erythroid cell defects and decreased
RBC life span, and that Sox6
fl/flCaggCreER adult mice, which
inactivated Sox6 only upon tamoxifen injection, developed
erythroblast defects before anemia. The shorter half-life of RBCs
must have contributed to cause anemia, but its value at 19 instead
of 25 days was probably insufficient to justify the doubling of the
sEpo level and spleen size. It is likely that abnormal maturation of
RBCs reduced the functionality of these cells and thus contributed
to causing hypoxia. The enlargement of the spleen could have
several causes. We demonstrated that it was partly due to
increased in erythropoietic activity, since more erythroid colonies
could be generated in vitro from mutant spleens than from control
spleens. We showed that it was also due to a larger population of
erythroblasts. As previously reported for fetal liver erythroid cells
[30], erythroblasts from adult bone marrow and spleen were
impaired in maturing and thus delayed in entering the circulation.
Interestingly, we found that the erythropoietic tissues of adult
mutants had a reduced proportion of proerythroblasts, revealing
that Sox6 is needed to promote expansion of proerythroblasts. We
previously reported that Sox6 ablation in fetal liver primary
erythroid cells resulted in decreased survival and proliferation of
proerythroblasts [30]. Similar defects in proerythroblasts are thus
likely to occur in Sox6 mutant adult mice. They would explain that
erythropoietic tissues contained fewer proerythroblasts and that
BFU-Es formed more slowly from mutant than from wild-type
adult erythropoietic tissues in vitro. Our new data thus
demonstrate that Sox6 enhances definitive erythropoiesis in a
similar way in the fetus, young pup, and adult mouse. While this is
not entirely surprising, we could not have extrapolated the
conclusion previously drawn in young animals to adults without
experimentation since erythropoiesis occurs at a much lower rate
in the adult under steady-state conditions than in the rapidly
growing fetus and pup, and since major differences exist in
erythroid gene expression between fetuses and adult mice [48,49].
We demonstrated that Sox6 is more critically needed in adult
mice subjected to stress erythropoiesis than in mice under steady-
state conditions of erythropoiesis. Similar conclusions were
previously reached for other factors, such as Bcl-xL and Foxo3a,
and is explained by the fact that stress erythropoiesis is a much
more productive process than basal erythropoiesis and thus
critically relies on factors capable of boosting it. Sox6
fl/flErGFPCre
mice showed a mortality of 25% when subjected to acute anemia,
whereas all control mice survived. RBCs decayed at the same rate
in control and mutant mice and the sEpo level increased similarly
in both types of mice, ruling out increased sensitivity of mutants to
PHZ or inability to generate a sufficient surge in Epo level. The
hematocrit of control and mutant mice decreased by half within 2
days of PHZ injection, but remained at this low value much longer
in mutant than control mice. Such a low value is not life
threatening in a normal mouse. While the hematocrit of the
mutant mice that died could have further dropped, additional
defects could also have contributed to lethality. Reticulocytes were
maturation impaired, maintaining a high level of CD71 longer
than control cells. We tried to measure hemoglobin levels in the
first week after PHZ treatment, but the high degree of hemolysis at
that time did not permit accurate measurement. We previously
showed that the RBC hemoglobin content of Sox6
2/2 fetuses was
about 66% the normal value and that Sox6
2/2 primary erythroid
cells were delayed in hemoglobinizing [30]. It is thus possible that
the first RBCs released in mutant mice under stress were poorly
hemoglobinized. Moreover, their immature shape and possibly
other defects may have further reduced their ability to properly
deliver oxygen to tissues.
We showed that Sox6 has unique roles in stress erythropoiesis.
Sox6 is dispensable to generate the surge in sEpo level and the Epo-
mediated early response to acute anemia, which includes spleen
enlargement and massive production of proerythroblasts and early
erythroblasts. Further supporting the notion that Sox6 is not
involved in this early response was our observation that Sox6
expression increases in bone marrow and spleen only from day 4
to 7 after PHZ injection. We previously showed that Sox6 enhances
the ability of Epo signaling to promote proerythroblast survival
and proliferation in vitro [30] and we showed here that Sox6 is
needed probably in the same way to expand the population of
proerythroblasts in adult mice under physiological conditions. This
function of Sox6, however, is probably largely compensated for in
mutant mice subjected to acute anemia by the very high increase
in sEpo level. In contrast, the major role of Sox6 to promote
erythroblast maturation in the second phase of the stress
erythropoietic response, including cytoplasmic and nuclear
condensation, is not fully compensated. Such defects were seen
under basal conditions, but they were worsened under stress
conditions. Sox6 thus most critically control erythroid cells at the
terminal maturation stages at all mouse ages in both basal and
stress conditions for erythropoiesis.
We provided new insights into the mechanisms whereby Sox6
controls erythroid development at the molecular level by screening
gene expression microarrays and validating data with various
RNA and protein assays. Previous studies in fetuses and
hematopoietic chimeras revealed that the embryonic globin genes
are ectopically expressed in Sox6-deficient definitive erythroid cells
[30–33]. We have extended these findings to adult mice in both
basal and stress erythropoiesis conditions. Importantly, we have
also demonstrated that the globin RNA and protein levels are
negligible compared to those of adult globins and that these
proteins do not precipitate in the erythroid membranes and do not
increase the production of damaging reactive oxygen species, in
contrast that what is seen when abnormal ratios of globin proteins
are produced in thalassemia patients. Repression of embryonic
globin genes is thus unlikely to be the most consequential function
of Sox6 in erythroid cells. We found that many other genes were
upregulated or downregulated in the absence of Sox6. The
expression changes of these genes were only a few folds, a finding
consistent with the fact that Sox6 does not have a transactivation
or transrepression domain, and has been shown to act in other cell
types as a positive or negative modulator of gene expression [23].
One of the downregulated genes was Bcl2l1, which encodes the
anti-apoptotic factor Bcl-xL. Previous studies have shown that
Bcl2l1 is a direct target of Stat5 downstream of Epo signaling in
early erythroid cells [21], and that it is upregulated in late
erythroid cells in a Stat5-independent manner to promote
erythroblast and reticulocyte survival [22,50–52]. In agreement
with these studies, we showed that Bcl2l1 expression closely
parallels Sox6 expression in late erythroid cells and is dependent
upon both Epo signaling and Sox6. Further, we demonstrated that
both Sox6 and Stat5 are able to upregulate a Bcl2l1 reporter in
cultured cells, and their effects are additive rather than synergistic.
This result is consistent with the possibility that Stat5 and Sox6
both contribute to mediate Epo signaling in vivo but act
independently of each other rather than cooperatively. While
Stat5 is more critical in early erythroid cells, Sox6 is more critical
at later stages of erythroid cell development. Further studies in
vivo and in vitro will be needed to fully decipher how Stat5 and
Sox6 contribute to control Bcl2l1 expression at the various stages
of erythroid cell development and in response to Epo signaling.
Another interesting gene significantly downregulated in Sox6
mutants is Rnf11. Although its role in vivo remains unknown, it
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ring finger protein 11 product [53] may contribute to the
important roles that ubiquitination fulfills in erythroid cells. It
has been shown, for instance, that ubiquitination causes rapid
inactivation of EpoR upon ligand binding [54] and participates in
reticulocyte remodeling, including CD71 sorting into exosomes
[55]. Poor ubiquitination could thus account for several defects in
Sox6 mutants, including retention of CD71 on reticulocytes.
Together, these results thus strongly suggest that Sox6 facilitates
erythroid cell development by modulating the expression of a large
panel of marker genes.
Definitive RBCs are more efficient than primitive RBCs
because they are small, lack a nucleus, contain adult rather than
embryonic globins, and are long-lived. We have shown here that
Sox6 acts throughout adult life to facilitate erythropoiesis. It is
important in both basal and stress erythropoiesis. It ensures that
proerythroblasts properly expand and that RBCs are long-lived,
but its most critical roles are to ensure that the output of definitive
erythropoiesis is not delayed or decreased by the additional steps
of cell maturation required for erythroblast condensation and
enucleation. In addition to Epo treatments widely used to generate
an adequate burst of early erythroid cells in patients with various
anemia-causing conditions, one should thus also consider targeting
Sox6 to ensure timely maturation and release, as well as long life of
newly generated red blood cells.
Supporting Information
Table S1 List of gene expression changes in Sox6 mutant
samples versus control samples, as determined by microarray
screening.
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